Filters
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/659ae007051611659dd25984_Psychedelic%20Stool.jpeg)
Psychedelics
COMPASS Pathways And Greenbrook Are Partnering Up For Psychedelic Therapies
Psychedelic biotechnology company COMPASS Pathways (NASDAQ:CMPS) has entered into a new multi year research collaboration with Greenbrook TMS (NASDAQ:GNBH).
January 6, 2024
Biotech
Public Companies
Psychedelics
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/6598506e60cfdeac61f5ff9a_Atai%20Psychedelic.jpeg)
Psychedelics
atai Life Sciences is Taking a Psychedelic Investing Trip
atai Life Sciences (NASDAQ: ATAI) has announced they will invest $50 million into psychedelic drug developer Beckley Psytech
January 5, 2024
Biotech
Psychedelics
Public Companies
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/6594ce46c49cdafc18c66851_Ketamine%20Molecule.jpeg)
Psychedelics
At Home Ketamine Therapeutics For Fibromyalgia
Silo Pharma (NASDAQ: SILO) has received regulatory approval to advance their novel time release ketamine implant into preclinical research
January 1, 2024
Biotech
Public Companies
Psychedelics
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/658b52ba24c530bd5bd4880e_Clinic.jpeg)
Psychedelics
Australia Has Its First Dedicated Psychedelic Clinic
Incannex Healthcare (NASDAQ: IXHL) subsidiary Clarion Clinics has received regulatory approval to begin to administer psychedelic assisted therapies.
December 26, 2023
Public Companies
Biotech
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/657a0cba5541d55267b44134_MDMA.jpeg)
Psychedelics
MDMA Assisted Therapy Could Be Closer Than Ever
MAPS Public Benefit Corporation has just filed a New Drug Application with the FDA for MDMA assisted therapy to treat post traumatic stress disorder (PTSD).
December 12, 2023
Biotech
Psychedelics
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/657852b3dd0655710b75f2bf_Molecule.jpeg)
Psychedelics
Gilgamesh Psychedelic Trial Shows Promise in Mental Health and Beyond
Gilgamesh Pharmaceuticals has announced positive results from their Phase 1 trial of GM-2505, a novel 5-HT2A receptor agonist.
December 11, 2023
Biotech
Venture Capital
Psychedelics
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/656951aaa4f0c2e1cf84aaa6_Psilocybin%202.jpeg)
Psychedelics
Cybin is Seeing Positive Results For Psychedelics in Phase II Clinical Trials
Cybin (NYSE: CYBN) has announced positive data from their Phase II clinical trial for their novel psilocybin analog CYB003.
November 30, 2023
Biotech
Public Companies
![](https://cdn.prod.website-files.com/64c2a9ec9c767dc6142b968b/65351da9326250849fa65e3a_Harvard%20Mushroom.jpeg)
Psychedelics
Harvard Lands $16 Million For Psychedelic Research
Harvard University has received $16 million in new philanthropic funding to research psychedelic compounds for therapeutic potential.
October 21, 2023
Psychedelics
Biotech